ArticleBioinformatics advances2026
CDCR-Rank: a computational model for predicting drug combination dose response using ranking-based optimization.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Predicting synergistic drug combinations for cancer therapies is vital but challenged by interaction complexity and vast combinatorial possibilities. To address this, we propose a novel ranking-based approach for drug synergy prediction. Our method builds upon the pre-trained CDCR model to predict absolute synergy scores and introduces a novel architecture to directly compare a list of combinations. A key innovation is our custom loss function, which combines mean squared error with a ranking loss term to simultaneously learn accurate synergy values and their correct relative ordering. Results: We comprehensively evaluated our model, CDCR-Rank, on the NCI-ALMANAC benchmark under three challenging scenarios, including predicting synergy for novel drug pairs without monotherapy data. CDCR-Rank demonstrated superior performance, consistently outperforming state-of-the-art methods such as comboFM and comboLTR. Ablation studies validated the importance of each component: a one-dimensional convolutional neural network (1D-CNN) for generating task-specific drug representations from SMILES strings, a sinusoidal encoder for modeling non-linear dose-response curves, and the uRank loss for optimizing combination rankings. Our integrated framework achieves significantly improved accuracy and robustness in predicting drug synergy. By reliably prioritizing the most promising combinations for experimental validation, this work has the potential to accelerate the discovery of effective multi-drug cancer therapies. Availability and implementation: CDCR-Rank is implemented in Python and is available at https://github.com/ParvinRazzaghi/CDCR-Rank.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.